Literature for melagatran (S01.217 inhibitor)

(Topics flags: I Inhibitor, V Review. To select only the references relevant to a single topic, click the link above. See explanation.)

2005
1. Christersson,C., Oldgren,J., Bylock,A., Wallentin,L. and Siegbahn,A.
   Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction
   J Thromb Haemost3, 2245-2253. PubMed  Europe PubMed DOI  I
2. [YEAR:2-5-2005]Furugohri,T., Shiozaki,Y., Muramatsu,S., Honda,Y., Matsumoto,C., Isobe,K. and Sugiyama,N.
   Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models
   Eur J Pharmacol514, 35-42. PubMed  Europe PubMed DOI  I
3. [YEAR:15-7-2005]Gulseth,M.P.
   Ximelagatran: an orally active direct thrombin inhibitor
   Am J Health Syst Pharm62, 1451-1467. PubMed  Europe PubMed DOI  I
4. Mohapatra,R., Tran,M., Gore,J.M. and Spencer,F.A.
   A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era
   Am Heart J150, 19-26. PubMed  Europe PubMed DOI  V  I
2004
5. Bostrom,S.L., Hansson,G.F., Sarich,T.C. and Wolzt,M.
   The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma
   Thromb Res113, 85-91. PubMed  Europe PubMed DOI  I
6. [YEAR:18-11-2004]Brighton,T.A.
   The direct thrombin inhibitor melagatran/ximelagatran
   Med J Aust181, 432-437. PubMed  Europe PubMed  V  I
7. Crowther,M.A. and Weitz,J.I.
   Ximelagatran: the first oral direct thrombin inhibitor
   Expert Opin Investig Drugs13, 403-413. PubMed  Europe PubMed DOI  I
2003
8. Bostrom,S.L., Hansson,G.F., Kjaer,M. and Sarich,T.C.
   Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects
   Blood Coagul Fibrinolysis14, 457-462. PubMed  Europe PubMed DOI  I
9. Clement,B. and Lopian,K.
   Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug
   Drug Metab Dispos31, 645-651. PubMed  Europe PubMed DOI  I
10. Eriksson,U.G., Bredberg,U., Gislen,K., Johansson,L.C., Frison,L., Ahnoff,M. and Gustafsson,D.
    Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects
    Eur J Clin Pharmacol59, 35-43. PubMed  Europe PubMed DOI  I
11. [YEAR:19-2-2003]Sarich,T.C., Wolzt,M., Eriksson,U.G., Mattsson,C., Schmidt,A., Elg,S., Andersson,M., Wollbratt,M., Fager,G. and Gustafsson,D.
    Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects
    J Am Coll Cardiol41, 557-564. PubMed  Europe PubMed DOI  I
1999
12. Sanderson,P.E.
    Small, noncovalent serine protease inhibitors
    Med Res Rev19, 179-197. PubMed  Europe PubMed DOI  V  I
1998
13. Nilsson,T., Sjoling-Ericksson,A. and Deinum,J.
    The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin
    J Enzyme Inhib13, 11-29. PubMed  Europe PubMed  I